UC Davis Alpha Stem Cell Clinic receives $8 million from California’s stem cell agency

SourceUC Davis Health
Date Published12/14/2022
Author NameNadine A Yehya
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name UC Davis Alpha Stem Cell Clinic
Parent companyUC Davis
Type of work Manufacturing
Reshoring category:Reshoring
Year reshoring announced:2022
Domestically, the work will be done:In-house
Capital investment ($):8
State(s) reshored to:CA
If relevant, work nearshored to:-
Industry(ies):Chemicals, Medical Equipment & Supplies, Stem cell and gene therapy, clinical trials
Product(s) reshoredstem cell
What domestic positive factors made reshoring more attractive?Government Incentives, Proximity to customers/market, Skilled workforce availability/training
Find Reshoring Articles